| Line Item | 2023-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $268.8M | -6.0% |
| SG&A Expense | $73.3M | +2.4% |
| Operating Income | -$293.1M | -7.5% |
| Net Income | -$283.3M | -5.1% |
| EPS (Basic) | -$1.46 | -2.1% |
| EPS (Diluted) | -$1.46 | -2.1% |
| Line Item | 2023-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $133.5M | -24.5% |
| Short-term Investments | $71.7M | -71.0% |
| Current Assets | $213.5M | -52.0% |
| Total Assets | $565.3M | -31.3% |
| Current Liabilities | $64.5M | -42.2% |
| Total Liabilities | $277.8M | -14.1% |
| Stockholders' Equity | $287.5M | -42.4% |
| Line Item | 2023-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$253.6M | +12.6% |
| Capital Expenditures | $20.0M | -4.0% |
| Investing Cash Flow | $172.0M | -18.3% |
| Financing Cash Flow | $31.6M | +544.1% |
| Free Cash Flow | -$273.6M | +12.0% |